Soros Fund Management’s Neurocrine Biosciences NBIX Stock Holding History

Soros Fund Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-239,823	Closed	-$26.5M	–	244
2025 Q1	$26.5M	Buy	239,823 +39,823	+20%	+$5.04M	0.4%	69
2024 Q4	$27.3M	Buy	200,000 +50,000	+33%	+$6.18M	0.41%	67
2024 Q3	$17.3M	Sell	150,000 -44,776	-23%	-$6.14M	0.25%	89
2024 Q2	$26.8M	Buy	194,776 +35,000	+22%	+$4.8M	0.48%	55
2024 Q1	$22M	Sell	159,776 -25,224	-14%	-$3.44M	0.37%	77
2023 Q4	$24.4M	Buy	185,000 +130,000	+236%	+$15M	0.32%	80
2023 Q3	$6.19M	Buy	+55,000	New	+$5.79M	0.09%	146
2017 Q4	–	Sell	-11,300	Closed	-$692K	–	252
2017 Q3	$692K	Buy	11,300 +6,400	+131%	+$338K	0.02%	146
2017 Q2	$225K	Buy	+4,900	New	+$238K	﹤0.01%	190
2016 Q4	–	Sell	-11,322	Closed	-$573K	–	266
2016 Q3	$573K	Buy	+11,322	New	+$564K	0.01%	159
2016 Q2	–	Sell	-9,400	Closed	-$372K	–	220
2016 Q1	$372K	Buy	+9,400	New	+$373K	0.01%	183
2013 Q3	–	Sell	-200,000	Closed	-$2.68M	–	256
2013 Q2	$2.68M	Buy	+200,000	New	+$2.46M	0.03%	173

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Soros Fund Management's NBIX Position: Q2 2025 in Review

Soros Fund Management sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 239,823 shares — an estimated $26.5M sold.

Soros Fund Management first reported a position in NBIX in Q2 2013 and held it in 12 quarters. The position peaked at $27.3M in Q4 2024. 587 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

Soros Fund Management reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
Soros Fund Management sold 239,823 Neurocrine Biosciences shares in Q2 2025, an estimated $26.5M.
Soros Fund Management first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 12 quarters.
Soros Fund Management's Neurocrine Biosciences position peaked at $27.3M in Q4 2024.
587 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Soros Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.